Show overview
Oncology Data Advisor has been publishing since 2021, and across the 5 years since has built a catalogue of 459 episodes. That works out to roughly 110 hours of audio in total. Releases follow a several-times-a-week cadence.
Episodes typically run ten to twenty minutes — most land between 7 min and 17 min — though episode length varies meaningfully from one episode to the next. None of the episodes are flagged explicit by the publisher. It is catalogued as a EN-language Science show.
The show is actively publishing — the most recent episode landed 3 weeks ago, with 32 episodes already out so far this year. The busiest year was 2023, with 166 episodes published. Published by Oncology Data Advisor®.
From the publisher
The mission of Oncology Data Advisor is to provide the multidisciplinary team with expert insights into clinical best practices and research progress in cancer care.
Latest Episodes
View all 459 episodesPersonalizing Surgical Risk Assessment in Lung Cancer With AI
Clinical Trial Enrollment Barriers: Awareness Isn’t the Same as Access
Building Trust in Real-World Evidence With AI and High-Quality Data
One Size Fits One: Personalizing Cancer Prevention Through AI-Enhanced Imaging
AI-Driven Pathological Subtyping for Pancreatic Cancer: Moving From Promise to Practical Application
Advancing Extrapulmonary NEC: DLL3 & Beyond
Prostate Cancer Breakthroughs: TALAPRO-3, PROTEUS, & Earlier Therapy
Advances in CIDP: Consensus Definitions, Emerging Pipeline & Individualized Care
Information Overload and the Portal Patient: The Era of Instant Test Results
One Size Fits One: Personalizing Cancer Prevention Through AI-Enhanced Imaging
Precision Decisions in NDMM: Live Virtual Rounds Preview
Multidisciplinary Realities: Tumor Board vs Tuesday Afternoon
The Real World vs The Trial Patient: Bridging the Gap
AI-Driven Pathological Subtyping for Pancreatic Cancer: Moving From Promise to Practical Application
Solving the PFIC Mystery: Genetic Testing and Diagnosis in Adults
Melanoma in Minutes: New Advances in Care—Available Through April 29
Melanoma in Minutes: Expert Strategies to Optimize Care—Available Through April 29
HelioLiver: Expanding Early Detection of Hepatocellular Carcinoma With AI
New Frontiers in Esophagogastric Cancer with Dr. Yelena Janjigian
The treatment of esophagogastric cancer is undergoing a profound transformation. In this episode, Yelena Janjigian, MD (MSKCC), discusses how perioperative chemoimmunotherapy and precision biomarkers are redefining the standard of care. Key highlights include: - The Perioperative Shift: Why starting immunotherapy before surgery is achieving unprecedented pathologic responses. - Precision Testing: The essential role of MSI, PD-L1, HER2, and CLDN18.2 testing for every patient. - Avoiding Understaging: Why clinical evaluation must go beyond imaging to prevent missed therapeutic opportunities. - Multidisciplinary Success: The critical need for surgeon-oncologist communication before the first incision. Tune in to learn why "cure" is the new benchmark in localized disease and how to integrate these advances into your clinical practice today. Interested in the complete CE activity? Complete Module 1: https://bit.ly/45u106o Complete Module 2: https://bit.ly/3HtOziO
HER2-Mutant NSCLC Update: Expanded Approval of Zongertinib
Click here to view the full CME/NCPD/CPE/AAPA activity and hear additional insights on the HER2-mutant NSCLC treatment landscape! https://i3health.com/course-information/nsclc-advances The FDA’s recent expanded approval of zongertinib marks a significant milestone in the treatment of non-small cell lung cancer (NSCLC). As the first oral human epidermal growth factor receptor 2 (HER2) inhibitor to move into the frontline setting, this therapy offers a new standard of care for patients with metastatic or unresectable non-squamous NSCLC harboring HER2 mutations. Following the approval, Beth Sandy, Thoracic Oncology Nurse Practitioner at the University of Pennsylvania, sat down to explore its clinical implications, including efficacy data, side effect management, and the potential of having a once-daily oral pill for improving patient experiences.